Cargando…

Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study

To investigate the prognoses associated with different locations of medulloblastoma (MB) in terms of survival through a case-control study and evaluate the prognostic factors for MB. The Surveillance, Epidemiology, and End Results database was used to identify MB patients diagnosed from 1975 to 2016...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qilin, Huang, Dezhi, Jiang, Yugang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544264/
https://www.ncbi.nlm.nih.gov/pubmed/33031272
http://dx.doi.org/10.1097/MD.0000000000022366
_version_ 1783591823696986112
author Qin, Qilin
Huang, Dezhi
Jiang, Yugang
author_facet Qin, Qilin
Huang, Dezhi
Jiang, Yugang
author_sort Qin, Qilin
collection PubMed
description To investigate the prognoses associated with different locations of medulloblastoma (MB) in terms of survival through a case-control study and evaluate the prognostic factors for MB. The Surveillance, Epidemiology, and End Results database was used to identify MB patients diagnosed from 1975 to 2016. Each brainstem MB (bMB) patient was matched to a cerebellum MB (cMB) patient by propensity score matching based on age, sex, tumor size, extent of metastasis, extent of surgical resection, radiotherapy status and chemotherapy status. Univariate and multivariate analyses were performed to assess the effect of prognostic factors on overall survival. Ethical approval was not necessary as this study is based on a public database. A total of 172 bMB patients and 1417 cMB patients were included in the study. A total of 144 pairs of patients were matched to constitute the matched cohort. Within the matched cohort, the median survival times were 213 months and 96 months for cMB and bMB, respectively. Within the unmatched cohort, the median survival times were 111 months and 97 months for cMB and bMB, respectively. Brainstem location detrimentally affected the survival time of MB patients in both the matched cohort (hazard ratios =8.14, 95% confidence interval =5.98–11.08) and the unmatched cohort (hazard ratios =1.44, 95% confidence interval =1.20–1.74). Age <5 years and receipt of radiotherapy were favorable prognostic factors, whereas gross total resection, brainstem location and receipt of chemotherapy were unfavorable prognostic factors. Radiotherapy alone was associated with superior outcomes concerning adjuvant chemotherapy or radiotherapy. This study uncovers a survival advantage for cMB patients versus bMB patients. Additionally, prognostic factors include age, extent of surgical resection, and receipt of radiotherapy or chemotherapy. Radiotherapy after surgery and rational use of chemotherapy drugs are crucial for treatment of MB patients. Further studies of these prognostic factors are required to improve the survival time.
format Online
Article
Text
id pubmed-7544264
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75442642020-10-30 Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study Qin, Qilin Huang, Dezhi Jiang, Yugang Medicine (Baltimore) 5700 To investigate the prognoses associated with different locations of medulloblastoma (MB) in terms of survival through a case-control study and evaluate the prognostic factors for MB. The Surveillance, Epidemiology, and End Results database was used to identify MB patients diagnosed from 1975 to 2016. Each brainstem MB (bMB) patient was matched to a cerebellum MB (cMB) patient by propensity score matching based on age, sex, tumor size, extent of metastasis, extent of surgical resection, radiotherapy status and chemotherapy status. Univariate and multivariate analyses were performed to assess the effect of prognostic factors on overall survival. Ethical approval was not necessary as this study is based on a public database. A total of 172 bMB patients and 1417 cMB patients were included in the study. A total of 144 pairs of patients were matched to constitute the matched cohort. Within the matched cohort, the median survival times were 213 months and 96 months for cMB and bMB, respectively. Within the unmatched cohort, the median survival times were 111 months and 97 months for cMB and bMB, respectively. Brainstem location detrimentally affected the survival time of MB patients in both the matched cohort (hazard ratios =8.14, 95% confidence interval =5.98–11.08) and the unmatched cohort (hazard ratios =1.44, 95% confidence interval =1.20–1.74). Age <5 years and receipt of radiotherapy were favorable prognostic factors, whereas gross total resection, brainstem location and receipt of chemotherapy were unfavorable prognostic factors. Radiotherapy alone was associated with superior outcomes concerning adjuvant chemotherapy or radiotherapy. This study uncovers a survival advantage for cMB patients versus bMB patients. Additionally, prognostic factors include age, extent of surgical resection, and receipt of radiotherapy or chemotherapy. Radiotherapy after surgery and rational use of chemotherapy drugs are crucial for treatment of MB patients. Further studies of these prognostic factors are required to improve the survival time. Lippincott Williams & Wilkins 2020-10-09 /pmc/articles/PMC7544264/ /pubmed/33031272 http://dx.doi.org/10.1097/MD.0000000000022366 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 5700
Qin, Qilin
Huang, Dezhi
Jiang, Yugang
Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
title Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
title_full Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
title_fullStr Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
title_full_unstemmed Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
title_short Survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
title_sort survival difference between brainstem and cerebellum medulloblastoma: the surveillance, epidemiology, and end results-based study
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544264/
https://www.ncbi.nlm.nih.gov/pubmed/33031272
http://dx.doi.org/10.1097/MD.0000000000022366
work_keys_str_mv AT qinqilin survivaldifferencebetweenbrainstemandcerebellummedulloblastomathesurveillanceepidemiologyandendresultsbasedstudy
AT huangdezhi survivaldifferencebetweenbrainstemandcerebellummedulloblastomathesurveillanceepidemiologyandendresultsbasedstudy
AT jiangyugang survivaldifferencebetweenbrainstemandcerebellummedulloblastomathesurveillanceepidemiologyandendresultsbasedstudy